Good MorningU.S. stock markets were relatively calm again on Tuesday as traders gear up for the Q1 earnings onslaught. The S&P 500 was able to edge higher but by less than half a percent to set a new all-time high. The market is being led higher by the analyst’s sentiment and a rising consensus for Q1 results. The risk for the market is that with the S&P 500 so highly valued there is a risk Q1 earnings could turn into a sell-the-news event.
Trading could take on a different tone after today. Between expected earnings reports from the big banks and economic data in the form of the Fed’s Beige Book, there is a lot of risk for the market. Among those reporting are J.P. Morgan, Goldman Sachs, and Wells Fargo. As for the Beige Book, the market will be watching it closely for any signs of rising inflation and there are sure to be some.
Featured: No AI Bots. Just Real Signals. Start Your Market Pulse Subscription Today (Ad) 
|
Technology | | NXP Semiconductors (NASDAQ: NXPI) had a rough 2020. The company – which derives nearly half of its revenue from its automotive business – saw full-year revenue drop 3% yoy to $8.6 billion.
But that 3% dip doesn’t tell the whole story – it was an uneven year for NXP. In the s... Read the Full Story |
|
From Our Partners | | Market liquidity has reached levels never seen before, with more money changing hands in the S&P 500 each day than at any prior point in history.
Trader Chris Pulver calls these moments Flashpoints - short windows tied to forced momentum that he breaks down in a new live session recorded from his home in Utah.
No guarantees are made, but the setup and strategy behind Flashpoints are laid out in full detail. | | Watch the free breakdown to learn how Flashpoints work |
|
Materials | | It’s safe to say that one of the biggest concerns that economists and investors have on their minds at this time is inflation. With historic amounts of fiscal stimulus being added to the economy and steadily increasing government spending, many believe that widespread inflation is already occu... Read the Full Story |
|
Finance | | Back in March 2020, when lockdowns began and businesses were shut down, investors lost confidence in everything, even online payment systems such as PayPal (NASDAQ: PYPL), Square (NYSE: SQ) and Shift4 (NYSE: FOUR).
Analysts and investors initially expected economic devastation, not anticipating th... Read the Full Story |
|
From Our Partners | | A 30-year trading veteran who managed multi-million-dollar hedge funds and wealth for one of the world's richest families is sharing his day trading rules for free.
His approach includes the criteria behind a 94.5% win rate, methods for spotting quality stocks already moving higher, and tips for avoiding cutting winners too early. | | Download the free day trading playbook and start spotting winning stocks today |
|
Markets | |
In the world of professional sports, defense often wins championships. In stock investing, defensive companies typically don't produce championship caliber returns. This role is usually best left for cyclical, high-growth stocks.
Sometimes, however, the tables are turned, and the defense goes on ... Read the Full Story |
|
Markets | | Media company Discovery Networks (NASDAQ: DISCA) stock experienced a questionable price surge on the coattails of peer Viacom (NYSE: VIAC). Subsequently, Discovery Networks shares also shadowed Viacom’s implosion and volatility as news of Archegos Capital Management margin calls triggered forc... Read the Full Story |
|
From Our Partners | | You've seen the crypto market… it's absolutely on fire. And the biggest catalyst could be up next. September 15. That's when the Senate's cloture motion on the Clarity Act is scheduled to come due… the first major floor test for a bill designed to finally give America clear rules for digital assets.
The market is rallying before that vote even happens... Crypto is already ripping before the most important bill for the market has passed.
We believe we've found the altcoin that could benefit the most from this bill… And given the current move in the market, we are recommending it right now. | | Get Our #1 CLARITY Act Coin Pick. |
|
Finance | |
When a company has a high-profit margin, this can be a sign of a strong business model, pricing power, a competitive advantage, or all of the above. It can also translate into excellent earnings growth and above-market returns for shareholders.
While big gains can result from rolling the dice on ... Read the Full Story |
|
Consumer Discretionary | | Lovesac Is A Couch Every Parent Should Own
We began to fall in love with the Lovesac (NASDAQ: LOVE) hyper-growth story last year. The company’s robust double-digit growth was unfazed by the pandemic and was in fact accelerating in the second half of the year. Since then we’ve learned m... Read the Full Story |
|
Markets | |
During the Reddit-fueled short squeeze days of late-January Bed Bath & Beyond (NASDAQ:BBBY) was among the companies targeted by retail traders. In a matter of a few days the highly shorted stock doubled making it one of the most notorious meme stocks.
Three months later, the stock has returne... Read the Full Story |
|
Industrials | |
Spirit Airlines (NYSE: SAVE) and JetBlue (NASDAQ: JBLU) are the latest two airlines to grab the attention of Wall Street as the economic recovery continues to gather pace. Last week we covered similar moves with United (NASDAQ: UAL) and Alaska (NYSE: ALK) so it’s clear the upside potential i... Read the Full Story |
|
Technology | | It’s safe to say that NVIDIA (NASDAQ:NVDA) just had a very successful investor day given the price action of the stock following the event. Investor days can be hit or miss for companies depending on what their respective management teams have planned and the market’s overall reception o... Read the Full Story |
|
The Early Bird Stock Of The Day Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. | | View Today's Stock Pick |
|
